NUFIL-SAFE 300MCG/0.5ML INJECTION

Indications

• Neutropenia
• Infection prevention during chemotherapy
• Bone marrow suppression
• Acute myeloid leukaemia
• Hematopoietic stem cell transplantation

Dosage

Children: Refer to the BNF for Children for appropriate dosing.

Adults: Refer to the specific product information and clinical guidelines for appropriate dosing.

Mechanism of action

Colony-stimulating factors bind to specific receptors on the surface of hematopoietic stem cells in the bone marrow, activating signaling pathways that promote cell proliferation and differentiation into various types of blood cells, particularly granulocytes. This leads to an increased production of neutrophils, enhancing the body’s immune response.

Pharmacodynamics

CSFs increase the number of circulating neutrophils in the blood, which can help to prevent infections in patients with neutropenia. They act by enhancing the survival, proliferation, and differentiation of myeloid progenitor cells, thus accelerating the recovery of neutrophil counts after chemotherapy or bone marrow suppression.

Pharmacokinetics

Colony-stimulating factors are typically administered subcutaneously or intravenously. They exhibit a rapid onset of action, with peak effects usually observed within 24 to 48 hours post-administration. The elimination half-life varies depending on the specific CSF used, but generally, they are cleared from the bloodstream through a combination of receptor-mediated endocytosis and renal excretion.

Pregnancy

Colony-stimulating factors like colony-stimulating factor (CSF) are generally considered safe during pregnancy, but should be used only if clearly needed.

Breast-feeding

It is not known whether colony-stimulating factors are excreted in human milk. Caution should be exercised when administered to breastfeeding women.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Indications

• Hemophilia A
• Hemophilia B
• Von Willebrand disease
• Acquired bleeding disorders

Dosage

Children: Refer to the BNF for Children for appropriate dosing based on age and weight.

Adults: Refer to the BNF for specific dosing guidelines based on the type of factor concentrate and clinical scenario.

Mechanism of action

Factor acts by replacing the deficient or absent clotting factors in patients with hemophilia, thereby restoring the normal coagulation cascade. This process enhances thrombin generation, leading to increased fibrin formation and stabilization of the platelet plug at the site of vascular injury. It is crucial in the intrinsic pathway of the coagulation process.

Pharmacodynamics

The pharmacodynamic effects of Factor are primarily related to its role in promoting hemostasis. Following administration, Factor directly increases the levels of specific clotting factors in the bloodstream, which enhances the ability to form a stable blood clot. The onset of action can vary depending on the specific formulation and route of administration, typically beginning within minutes.

Pharmacokinetics

Factor exhibits a half-life that can vary from a few hours to over a day, depending on the specific factor concentrate used. It is primarily eliminated by the reticuloendothelial system. The pharmacokinetics may differ between individuals based on factors such as age, weight, and presence of inhibitors against the factor. Monitoring of factor levels may be necessary to adjust dosing and ensure adequate hemostatic effect.

Pregnancy

Use with caution. Consult with a healthcare provider for specific guidance.

Breast-feeding

Consult with a healthcare provider for specific guidance.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Diabetes mellitus
• Chronic kidney disease-related anemia
• Hemophilia
• Cancer (as targeted therapy)
• Autoimmune diseases (e.g., rheumatoid arthritis)

Dosage

Children: Refer to specific product guidelines for dosing information.

Adults: Refer to specific product guidelines for dosing information.

Mechanism of action

Recombinant drugs function by mimicking the action of naturally occurring proteins in the body. For instance, recombinant insulin binds to insulin receptors on target tissues, facilitating glucose uptake and metabolism. Erythropoietin stimulates erythropoiesis by binding to erythropoietin receptors in the bone marrow, promoting the production of red blood cells.

Pharmacodynamics

The pharmacodynamics of recombinant drugs vary depending on the specific protein or hormone being replaced or supplemented. Generally, they exert their effects at the cellular level by interacting with specific receptors, leading to a cascade of biological responses. The therapeutic effects are usually dose-dependent and can vary based on the patient's biological response and the presence of antibodies against the recombinant product.

Pharmacokinetics

Pharmacokinetics of recombinant drugs include absorption, distribution, metabolism, and excretion (ADME) characteristics that can differ significantly based on the specific drug. Many recombinant proteins have a short half-life and require parenteral administration. They are typically distributed throughout the body via the bloodstream, metabolized by the liver and other tissues, and excreted primarily through the kidneys. The pharmacokinetics may be influenced by the patient's age, weight, and overall health.

Pregnancy

Recombinant proteins should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering recombinant proteins during breastfeeding, as the effects on the infant are not well established.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze, and protect from light.

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy
• Obesity (as part of a comprehensive weight management program)
• Treatment-resistant depression
• Cognitive enhancement in certain disorders

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on age and weight.

Adults: Refer to the specific BNF for individual stimulant medications for appropriate dosing guidelines.

Mechanism of action

Stimulants enhance the release of neurotransmitters such as dopamine and norepinephrine in the brain. They inhibit the reuptake of these neurotransmitters, leading to increased synaptic concentrations and prolonged effects. This mechanism is particularly relevant in the treatment of ADHD, where increased dopamine activity in the prefrontal cortex can improve attention and behavior regulation.

Pharmacodynamics

Stimulants generally exert their effects by increasing neurotransmitter availability in the synaptic cleft, leading to enhanced neuronal firing rates. This results in improved cognitive function, mood elevation, and increased physical activity. The specific pharmacodynamic profile can vary between different stimulant medications, with some exhibiting a more pronounced effect on dopamine versus norepinephrine pathways.

Pharmacokinetics

Stimulants are typically well absorbed in the gastrointestinal tract and may have varying half-lives depending on the formulation (immediate vs extended release). They are metabolized primarily in the liver, and their elimination is often through the kidneys. The onset of action can range from minutes to hours, with effects lasting from a few hours to over 12 hours in some extended-release forms.

Pregnancy

The use of stimulating agents during pregnancy should be approached with caution due to potential risks to fetal development. It is essential to weigh the benefits against possible adverse effects.

Breast-feeding

Caution is advised when using stimulating agents while breastfeeding, as they may pass into breast milk and affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the container is tightly closed to maintain stability.